Earnings summaries and quarterly performance for Alphatec Holdings.
Executive leadership at Alphatec Holdings.
Patrick S. Miles
Detailed
President and Chief Executive Officer
CEO
AS
Ali Shorooghi
Detailed
Senior Vice President, Marketing
CE
Craig E. Hunsaker
Detailed
Executive Vice President, People & Culture
DP
David P. Sponsel
Detailed
Executive Vice President, Sales
JT
J. Todd Koning
Detailed
Executive Vice President and Chief Financial Officer
JW
Joseph Walland
Detailed
Senior Vice President, Imaging Solutions
SL
Scott Lish
Detailed
Chief Operating Officer
TM
Tyson Marshall
Detailed
General Counsel & Corporate Secretary
Board of directors at Alphatec Holdings.
Research analysts who have asked questions during Alphatec Holdings earnings calls.
DS
David Saxon
Needham & Company
4 questions for ATEC
Also covers: ALC, ALGN, AZTA +11 more
BH
Ben Haynor
Lake Street Capital Markets
3 questions for ATEC
Also covers: APYX, BFLY, CLGN +9 more
BO
Brooks O'Neil
Lake Street Capital Markets
3 questions for ATEC
Also covers: ARAY, BBNX, DYNT +11 more
Matthew Miksic
Barclays PLC
3 questions for ATEC
Also covers: ABT, BAX, BDX +15 more
CC
Caitlin Cronin
Canaccord Genuity
2 questions for ATEC
Also covers: AXGN, BVS, ENOV +12 more
EA
Eric Anderson
TD Cowen
2 questions for ATEC
Also covers: CERS, RBOT, RCEL +2 more
JW
Jason Wittes
Roth Capital Partners, LLC
2 questions for ATEC
Also covers: ALUR, ARAY, CV +13 more
JJ
Joshua Jennings
TD Cowen
2 questions for ATEC
Also covers: ABT, ALUR, BDX +21 more
MB
Mathew Blackman
Stifel
2 questions for ATEC
Also covers: AHCO, BBNX, CERS +10 more
MB
Matthew Blackman
TD Cowen
2 questions for ATEC
Also covers: BBNX
MS
Michaela Smith
Canaccord Genuity
2 questions for ATEC
Also covers: KRMD, OFIX, VCEL
VC
Vikramjeet Chopra
Wells Fargo & Company
2 questions for ATEC
Also covers: ALGN, CNMD, ENOV +9 more
XL
Xun Lee
H.C. Wainwright & Co., LLC
2 questions for ATEC
Also covers: CRVS, CTSO, EDAP +2 more
YL
Young Li
Jefferies
2 questions for ATEC
Also covers: ALC, ARAY, BLCO +8 more
Andrew Ranieri
Morgan Stanley
1 question for ATEC
Also covers: SIBN
Kallum Titchmarsh
Morgan Stanley
1 question for ATEC
Also covers: AXNX, EMBC, INSP +6 more
MO
Matthew O'Brien
Piper Sandler & Co.
1 question for ATEC
Also covers: APYX, ATRC, BBNX +18 more
Matt Miksic
Barclays Investment Bank
1 question for ATEC
Also covers: ABT, ALC, BAX +16 more
PD
Phillip Dantoin
Piper Sandler
1 question for ATEC
Also covers: CNMD, FNA, PODD +2 more
SM
Samantha Munoz
Piper Sandler Companies
1 question for ATEC
Also covers: CVRX, PEN, TELA +1 more
Sean Lee
H.C. Wainwright & Co.
1 question for ATEC
Also covers: CASI, CTSO, MYO +3 more
VC
Vik Chopra
Wells Fargo & Company
1 question for ATEC
Also covers: ALGN, CNMD, ENOV +8 more
Recent press releases and 8-K filings for ATEC.
Alphatec Holdings Reports Strong Q4 and Full-Year 2025 Results, Provides Optimistic 2026 Guidance
ATEC
Earnings
Guidance Update
Product Launch
- Alphatec Holdings reported strong financial results for Q4 2025, with revenue of $213 million (up 20% year-over-year) and Adjusted EBITDA of $33 million (up 61% year-over-year). For the full year 2025, revenue reached $764 million (up 25%), and Adjusted EBITDA was $93 million.
- The company achieved its first full year of positive free cash flow in 2025, generating $3 million for the full year and $8 million in Q4 2025.
- Alphatec provided an optimistic full-year 2026 outlook, projecting revenue of approximately $890 million (17% growth), Adjusted EBITDA of $134 million (15% margin), and at least $20 million in free cash flow.
- Strategic advancements in 2025 included the release of a bone mineral density test out of EOS, pediatric tools, cervical products, 3D-printed implants, a corpectomy system, and new biologics. The company also plans a controlled release of its Valence integrated platform in 2026 and has an exclusive distribution partnership for a new BMP product.
3 days ago
Alphatec Holdings Reports Q4 and Full-Year 2025 Results, Provides 2026 Guidance
ATEC
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Alphatec Holdings (ATEC) reported Q4 2025 revenue of $213 million, a 20% year-over-year increase, contributing to full-year 2025 revenue of $764 million, up 25% from the prior year.
- The company demonstrated significant profitability improvements, with Q4 2025 Adjusted EBITDA growing 61% year-over-year to $33 million, and full-year 2025 Adjusted EBITDA reaching $93 million, an improvement of $63 million and 720 basis points compared to 2024.
- ATEC achieved its first full year of positive free cash flow in 2025, totaling $3 million, including $8 million generated in Q4 2025.
- For full-year 2026, ATEC projects revenue of approximately $890 million (17% growth), Adjusted EBITDA of $134 million (15% margin), and at least $20 million in free cash flow.
- Strategic initiatives in 2025 included new product releases like a bone mineral density test out of EOS, 3D-printed implants, and a corpectomy system, alongside continued leadership in lateral and deformity segments and an exclusive distribution partnership for a next-generation BMP.
3 days ago
Alphatec Holdings Reports Q4 and Full Year 2025 Financial Results, Updates 2026 Guidance
ATEC
Earnings
Guidance Update
Product Launch
- Alphatec Holdings reported Q4 2025 revenue of $213 million, a 20% year-over-year increase, with Adjusted EBITDA of $33 million, up 61% year-over-year. The company also generated $8 million in free cash flow for the quarter.
- For the full year 2025, total revenue reached $764 million, representing 25% growth compared to the prior year, and Adjusted EBITDA was $93 million. This marked the company's first full year of positive free cash flow at $3 million.
- The company provided 2026 revenue guidance of approximately $890 million and increased its Adjusted EBITDA guidance to $134 million, projecting a 15% Adjusted EBITDA margin for the full year.
- Alphatec announced an exclusive distribution partnership with Theradaptive for a next-generation BMP product, which is expected to be launched in the spine market in several years.
3 days ago
ATEC Reports Q4 and Full-Year 2025 Financial Results and Provides 2026 Outlook
ATEC
Earnings
Guidance Update
Product Launch
- Alphatec Holdings, Inc. (ATEC) reported full-year 2025 total revenue of $764 million, representing a 25% growth compared to the previous year, with Q4 2025 total revenue reaching $213 million.
- For the full year 2025, ATEC achieved Non-GAAP adjusted EBITDA of $93 million and generated $3 million in free cash flow, marking a pivotal milestone.
- The company provided a full-year 2026 revenue outlook of approximately $890 million and increased its adjusted EBITDA guidance to approximately $134 million, or 15% of revenue.
- ATEC also expects to generate at least $20 million of free cash flow for the full year 2026.
- During Q4 2025, ATEC announced the clearance and release of the Valence® intraoperative platform.
3 days ago
Alphatec Holdings Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Outlook
ATEC
Earnings
Guidance Update
Product Launch
- Alphatec Holdings (ATEC) reported full-year 2025 total revenue of $764 million, a 25% increase year-over-year, with Non-GAAP net income of $8 million and Non-GAAP adjusted EBITDA of $93 million.
- For the fourth quarter of 2025, ATEC achieved $213 million in total revenue, $9 million in Non-GAAP net income, and $33 million in Non-GAAP adjusted EBITDA, while also generating $8 million of free cash flow.
- The company provided a full-year 2026 revenue outlook of approximately $890 million, representing 17% growth, and increased its adjusted EBITDA guidance to approximately $134 million.
- ATEC expects to generate at least $20 million of free cash flow for the full year 2026, and announced the clearance and release of the Valence® intraoperative platform.
3 days ago
Alphatec Spine Reports Strong 2025 Results and Provides Upbeat 2026 Guidance
ATEC
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Alphatec Spine reported $764 million in revenue for 2025, a 25% increase, and projects $890 million in revenue for 2026, representing 17% growth.
- The company achieved $91 million in Adjusted EBITDA (12% of revenue) in 2025 and forecasts $130 million (15% margin) in 2026, with positive free cash flow in 2025 and $20 million in 2026.
- Strategic initiatives include strengthening its position as the third largest U.S. market share holder through proceduralization and informatics, with the Valence navigation and robotic tool expected to launch in 2026.
- Alphatec Spine remains committed to its 2027 long-range plan targets of $1 billion in revenue and $180 million in Adjusted EBITDA.
Jan 13, 2026, 11:45 PM
Alphatec Spine Reports Strong 2025 Performance and Provides 2026 Guidance
ATEC
Guidance Update
Revenue Acceleration/Inflection
Product Launch
- Alphatec Spine (ATEC) finished 2025 with $764 million in revenue, representing 25% growth, and achieved $91 million in Adjusted EBITDA, reaching free cash flow profitability.
- The company became the third largest U.S. market share holder in 2025 and projects $890 million in revenue for 2026, a 17% increase, with $130 million in Adjusted EBITDA and $20 million in free cash flow.
- ATEC's strategy focuses on clinical distinction and proceduralization, driven by informatics tools like SafeOp, EOS, and the upcoming Valence navigation and robotic tool launching in 2026.
- The company anticipates a new seasonality pattern, with stronger Q3s due to its growing presence in pediatric deformity, and views disruption from competitor spin-offs as advantageous.
Jan 13, 2026, 11:45 PM
Alphatec (ATEC) Discusses Strong 2025 Performance and Provides 2026 Financial Guidance
ATEC
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Alphatec (ATEC) reported $764 million in revenue for 2025, reflecting 25% growth, with $91 million in adjusted EBITDA (12% of revenue) and positive cash flow.
- For 2026, the company projects $890 million in revenue (17% growth), $130 million in adjusted EBITDA (15% margin), and $20 million in free cash flow.
- Alphatec aims to achieve $1 billion in revenue, $180 million in adjusted EBITDA (18% margin), and $65 million in free cash flow by 2027.
- The company's strategy emphasizes proceduralization, particularly in lateral surgery, and significant investment in informatics through systems like EOS Insight, SafeOp, and the Valence navigation and robotic tool, which is set to launch in 2026.
- Alphatec became the third largest U.S. market share holder in 2025, with 2026 growth expected to be driven by $118 million in surgical growth and $8 million in EOS growth, targeting $100 million in EOS revenue by 2027.
Jan 13, 2026, 11:45 PM
Alphatec Holdings and Theradaptive Announce Strategic Partnership for Spinal Fusion Technology
ATEC
New Projects/Investments
- Alphatec Holdings (ATEC) has secured exclusive U.S. commercial rights to market and distribute Theradaptive's OsteoAdapt® osteoinductive bone graft for spinal fusion through a definitive strategic partnership. The agreement includes upfront and milestone payments to Theradaptive, along with a perpetual royalty structure.
- OsteoAdapt, utilizing AMP2™ protein technology, is currently in clinical trials, subject to FDA PMA approval, and has received three FDA Breakthrough Device Designations. This technology targets the $2+ billion biologics segment within the $10+ billion U.S. spine surgery market.
- To support the completion of clinical studies and rapid scaling of its technology platform, Theradaptive has initiated a Series B investment round.
Jan 12, 2026, 2:30 PM
Alphatec Holdings, Inc. Announces Preliminary 2025 Results and 2026 Outlook
ATEC
Earnings
Guidance Update
New Projects/Investments
- Alphatec Holdings, Inc. announced preliminary unaudited financial results for the full year ended December 31, 2025, with total revenue growing 25% to approximately $764 million and re-affirming adjusted EBITDA guidance of $91 million.
- The company provided a financial outlook for full-year 2026, anticipating total revenue of $890 million, reflecting approximately 17% growth compared to 2025, and adjusted EBITDA of $130 million, which is expected to contribute to $20 million in free cash flow.
- ATEC also announced the acquisition of exclusive U.S. distribution rights for Theradaptive’s OsteoAdapt®, a next-generation rhBMP-2 biologic, which expands the company's procedural offerings.
Jan 12, 2026, 2:10 PM
Quarterly earnings call transcripts for Alphatec Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more